Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting OSLO, Norway, April 08, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...

Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting OSLO, Norway, March 08, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...

Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference OSLO, Norway, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...

Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer Nykode Therapeutics has reached the enrollment target of 50 patients in its VB C-02 trial for the treatment of advanced cervical cancerInterim efficacy and safety data expected in 1H 2022 OSLO,...

Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate First subject dosed with Nykode Therapeutics’ T cell focused SARS-CoV-2 vaccine candidate. This is part of the ongoing phase 1/2 two-arm clinical trial VB-D-01 designed to specifically address...